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Multi-drug combinations are vital in modern medicine (Keith
etal,2005;Fitzgeraldetal,2006). Suchdrugcombinationscan
also be used to probe the relationships between proteins in a
network, and progress towards using drug interactions to infer
networkconnectivity has been made in recent years.Acurrent
study by Leha ´r et al (2007) takes this effort a large step further
by developing tools to use the entire data in a drug–drug
interaction dose–response surface to give useful information
on the networks in which the drug targets are embedded.
Classically, combinations of perturbations—drugs or muta-
tions—have been categorized into one of three interaction
types: additive, synergistic, or antagonistic (Bliss, 1939;
Loewe, 1953; Hartman et al, 2001). The expected null
interaction is called additive, although exactly howthis should
bedeﬁnedhasbeenasubjectofsomecontroversy(Bliss,1939;
Loewe, 1953; Greco et al, 1995). Synergy occurs when the
combination of two perturbations has an effect greater than
expected from the individual effects of the single perturba-
tions. Antagonism describes a combination with less than
expected effect. These classiﬁcations have proved powerful in
dissecting the modularity and connectivity of the underlying
biological networks (Tong et al, 2001; Schuldiner et al, 2005;
Segre et al, 2005; Yeh et al, 2006). There are some intuitive
expectations for combined effects of two drugs. Let us say, for
example, that drugs A and B block two alternative metabolic
pathways, of which at least one is needed. In this case, each
drug may have very little effect, but the combination will be
strongly synergistic. Similarly, antagonistic interaction may
resultfromdrugsactingontwoparallelpathwaysthat areboth
needed: inhibition of one pathway can make its product a
limiting factor, thereby neutralizing the effect of inhibition of
other pathways. This simple intuition can be elaborated and
applied at the system level to analyze a complex interaction
network composed of additive, synergistic, and antagonistic
links (Tong et al, 2001; Schuldiner et al, 2005; Segreet al, 2005;
Yeh et al, 2006).
But the three classical interaction types represent a radical
simpliﬁcation for drug combinations. Many drug combina-
tions exhibit different types of interactions ‘within a drug pair’
depending on dose. Drugs may be additive at one set of
combined concentrations and synergistic or antagonistic in
another. ‘Response surfaces’ (also represented by ‘isobolo-
grams’), which show combined drug effects over a 2-D
gradient of concentrations, can exhibit a rich set of patterns.
Can we use the abundant information in these response
surfaces to infer more speciﬁc and detailed information
regarding the underlying biological network?
Leha ´r et al (2007) used simulated Michaelis–Menten
metabolic pathways to ask whether drug–response surfaces
can yield information regarding the underlying connectivity of
molecular targets (Figure 1). They experimentally tested the
results of their simulations in the well-studied sterol metabo-
lism pathway. Indeed, in both simulation and experiments,
different drug pairs showed different complex response
surfaces. Knowing the underlying connectivity of the system,
it was then possible to establish links between various local
network topologies and the different response surfaces.
Leha ´r et al (2007) produced a reference set of four response
surface modelstowhich experimental data could be classiﬁed.
They found in their simulations that particular target
connectivities produced distinct responses in terms of these
shape models. The ﬁrst reference model, based on the
standard Loewe dose additivity (Loewe, 1953), is a best ﬁt
for combinations of drugs that affect the same target. A second
shape model,‘Bliss Boost’, an extension of the statistical Bliss
independence (Bliss, 1939), provided the best ﬁts for separate
targets in an unregulated pathway. A third model, ‘Highest
Single Agent’, assumes that the inhibition for the combined
drugs equal the highest (the most limiting) single drug
inhibition (Yeh et al, 2006), and was found to predominate
for cross-pathway combinations. A fourth model of ‘Potentia-
tion’, which allows an inherent asymmetry in the response
surface where the presence of a certain drug increases or
decreases the effective concentration of another, was found to
be a better ﬁt when cellular targets of drugs are in pathways
regulated by negative feedback.
This paper highlights the utility of models and simulations
for a task as critical as that of rationalizing and modeling the
effect of drug combinations. Indeed, quantitative approaches
to drug interactions have had impact in pharmacology for
more than a century. In the mid-nineteenth century, Fraser
(1872) published a landmark paper that showed how two
drugs, atropia and physostigma, can have hyperantagonistic
effects that resulted in one drug reversing the effects of the
other (Fraser, 1872). Fraser termed this ‘physiological anti-
dote’. Such suppressive interactions also exist in antimicrobial
agents (Yeh et al, 2006). It would be interesting to explore
whether the Leha ´r et al’s (2007) approach can be extended
to link such hyperantagonistic suppressive interactions to
possible underlying connectivities of the biological network.
This study offers a ‘proof of principle’ that we can link the
rich functional information encoded in complete drug–drug
dose–response surfaces to the connectivity between biological
targets.It willbe interesting to see how farthis kind ofanalysis
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confound the analysis? To what extent is the mapping between
network topologies and response surfaces a one-to-one
function? Further, it would be important to extend this idea
tothreeormoredrugcomponents.Suchmulti-drugtreatments
are already being used, but there is little understanding of how
their response surface (or, more accurately in this case,
‘response spaces’) should behave. In the case of three-drug
combinations, the question of how to deﬁne additivity is even
more complicated than for two-drug combinations, as the null
expectation for additivity must be based not only on the effect
of the single drugs but also on pre-existing knowledge of all
their pairwise interactions. Leha ´r et al’s (2007) surface
responses and shape models offer an excellent starting point
for conceptual and experimental explorations of such combi-
nations of three or more drugs.
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Figure 1 The relationship between target connectivity and synergy for paired inhibitors. The underlying connectivity for two inhibitors A and B is shown schematically
along with intuitive expectations for their combined effect and the simulated dose-dependent response surfaces. (A) If their targets are serial in a pathway, A and B
should help each other reduce production. If they inhibit parallel pathways (B, C), the combination effect ought to reﬂect the rate-limiting reaction for required (‘AND’)
junctions but should be very synergistic for alternative (‘OR’) pathways. (D) More complex network topologies without an intuitive expectation can still be simulated.
Leha ´r et al (2007) sought to categorize and link the set of possible response surfaces to underlying network connectivity (Figure courtesy of J Leha ´r).
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